Antidepressant Effect of Heracleum moellendorffii Extract on Behavioral Changes in Astrocyte Ablation Mouse Model of Depression by Modulating Neuroinflammation through the Inhibition of Lipocalin-2.
Soonsang HongYunna KimYongJu KwonSeung-Hun ChoPublished in: Nutrients (2024)
Astrocyte dysfunction and inflammation play a pivotal role in depression. In this study, we evaluated the antidepressant properties of Heracleum moellendorffii root extract (HME), which is traditionally used for inflammation-related diseases, in a mouse model with astrocyte depletion that resembles the prefrontal cortex pathology of depressive patients. Mice were divided into four groups, with 10 mice per group. To induce astrocyte ablation in the mice's prefrontal cortex (PFC), we used astrocytic toxin L-alpha-aminoadipic acid (L-AAA) and administered HME orally at 200 and 500 mg/kg for 22 days. We utilized the tail suspension test (TST) to assess depression-like behaviors and the open field test (OFT) to evaluate anxiety-like activities. Additionally, astrocytic and inflammatory markers in the PFC were evaluated using immunohistochemistry and ELISA. The results showed that infusion of L-AAA significantly decreased the expression of astrocytic glial fibrillary acidic protein (GFAP), which was accompanied by increased depression and anxiety-like behaviors. However, HME significantly reversed these effects by dose-dependently enhancing GFAP expression and modulating inflammatory markers, such as TNF-α, IL-6, and particularly lipocalin-2, a master proinflammatory mediator. These results imply that HME contributes to the alleviation of depression and anxiety-like behaviors by promoting astrocyte recovery and reducing neuroinflammation, especially through lipocalin-2 inhibition.
Keyphrases
- prefrontal cortex
- oxidative stress
- mouse model
- sleep quality
- high fat diet induced
- depressive symptoms
- poor prognosis
- end stage renal disease
- major depressive disorder
- traumatic brain injury
- lipopolysaccharide induced
- rheumatoid arthritis
- binding protein
- newly diagnosed
- chronic kidney disease
- lps induced
- minimally invasive
- low dose
- type diabetes
- cerebral ischemia
- peritoneal dialysis
- wild type
- metabolic syndrome
- inflammatory response
- spinal cord injury
- brain injury
- radiofrequency ablation
- small molecule
- skeletal muscle
- catheter ablation
- blood brain barrier